Maturity-onset diabetes of the young and other monogenic diabetes

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Maturity-onset diabetes of the young is a clinical umbrella within monogenic diabetes, not a single condition. The classic pattern is early-onset, autosomal dominant diabetes across generations with retained C-peptide and absent diabetes autoantibodies, but penetrance varies and de novo variants occur. Testing should be phenotype-led through NHS genomic eligibility criteria rather than ordered as an indiscriminate panel. Establish the age and treatment at diagnosis for affected relatives, maternal versus paternal transmission, neonatal history, birth weight, renal or hearing features and laboratory trajectory. Review autoantibodies and endogenous insulin reserve when safe. A molecular diagnosis matters only if the laboratory classification, inheritance and clinical phenotype agree; uncertain or incidental variants require clinical genetics or expert diabetes interpretation and must not trigger treatment switches alone.

Management is genotype-specific. Heterozygous GCK variants reset glucose sensing, producing stable mild fasting hyperglycaemia with little treatment response or usual microvascular risk; most people need no glucose-lowering treatment, though pregnancy requires specialist assessment of likely fetal genotype and growth because maternal treatment can help or harm depending on whether the fetus shares the variant. HNF1A and HNF4A disorders cause progressive secretory failure and often respond to small sulfonylurea doses, with careful hypoglycaemia surveillance. HNF1B disease is syndromic and treatment is frequently insulin-based while renal, electrolyte and exocrine issues are managed. Maternally inherited diabetes with deafness raises mitochondrial disease, for which multisystem review and medicine cautions apply. Neonatal KCNJ11 or ABCC8 channel disease may permit transfer from insulin to high-dose sulfonylurea, but only in an experienced specialist service. Every confirmed result should generate a written plan for the individual, pregnancy, complications and relatives rather than ending at the laboratory report.

Key points

Monogenic diabetes results from a single-gene disorder and should be suspected when the phenotype does not fit common type 1 or type 2 mechanisms.
Clues include diagnosis young in life, diabetes in successive generations, negative autoantibodies, persistent endogenous insulin secretion and gene-specific extra-pancreatic features.
GCK-related hyperglycaemia is usually lifelong, mild and stable, often with fasting glucose around 5.5–8 mmol/L; treatment is generally unnecessary outside specialist pregnancy decisions.
HNF1A- and HNF4A-related diabetes commonly progresses and can be highly sensitive to low-dose sulfonylureas, so molecular confirmation may allow specialist-supervised transfer from insulin.
HNF1B disease often combines diabetes with renal developmental abnormalities, genital tract anomalies, hypomagnesaemia, abnormal liver tests or pancreatic exocrine dysfunction and may need insulin.
Diabetes diagnosed before six months is unlikely to be autoimmune type 1 and warrants urgent neonatal-diabetes genomic testing because some channel variants respond to specialist high-dose sulfonylurea therapy.
Use the current NHS National Genomic Test Directory and regional genomic laboratory eligibility route; a variant of uncertain significance is not a treatment instruction.
A confirmed pathogenic familial variant enables targeted testing and counselling for relatives, with consent, reproductive implications and privacy handled explicitly.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Autosomal dominant beta-cell variants

Pathogenic variants affecting glucose sensing or insulin secretion can cause early-onset diabetes across successive generations with retained endogenous insulin.

Syndromic monogenic disease

Single-gene disorders may combine diabetes with renal, hearing, pancreatic or neurological features that reveal the underlying diagnosis.

Neonatal channel disorders

Variants in beta-cell potassium-channel genes can present in infancy and may change treatment when confirmed by specialist genomic assessment.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
A beta-cell pathway is altered
A pathogenic variant changes glucose sensing, insulin transcription, cell development or ion-channel control rather than producing the usual polygenic type 2 mechanism.
2
Insulin secretion follows a gene-specific pattern
Some variants cause stable mild fasting hyperglycaemia, while others produce progressive secretory failure and increasing treatment need.
3
The variant affects relatives and other organs
Inheritance creates family risk, and syndromic genes can alter kidney, hearing, exocrine pancreas or pregnancy outcomes beyond glucose alone.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

GCK phenotype

Stable mild fasting hyperglycaemia from childhood, small glucose excursion, HbA1c often mildly raised and similar findings in a parent suggest GCK-related disease rather than progressive type 1 or type 2 diabetes.

HNF1A or HNF4A pattern

Diabetes developing in adolescence or early adulthood across consecutive generations, negative antibodies, retained secretion and marked sulfonylurea sensitivity supports a hepatic nuclear factor subtype.

HNF1B syndromic clues

Renal cystic or developmental abnormality, impaired renal function, genital tract anomaly, hypomagnesaemia, abnormal liver tests or pancreatic hypoplasia alongside diabetes should prompt HNF1B-focused assessment.

Mitochondrial inheritance

Diabetes transmitted through the maternal line with sensorineural deafness, short stature, neuromuscular or cardiac features suggests mitochondrial diabetes rather than autosomal dominant MODY.

Neonatal onset

Persistent diabetes before six months of age strongly suggests a monogenic cause; neurological features or a history of transient neonatal diabetes can help prioritise genes but do not replace testing.

Evidence against simple MODY

Multiple positive diabetes autoantibodies, absent C-peptide soon after diagnosis, severe insulin resistance without a matching gene phenotype or diabetes only in older relatives lowers the probability and redirects evaluation.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Three-generation diabetes pedigreeFirst step
Why
Define inheritance, age at onset, treatment, neonatal history and extra-pancreatic features before genomic selection.
Interpretation and limitations
Vertical transmission supports dominant disease; maternal-only transmission suggests mitochondrial inheritance. Absence of family history does not exclude a de novo variant or unrecognised mild GCK hyperglycaemia.
02
Diabetes autoantibodies
Why
Assess whether autoimmune beta-cell disease better explains young-onset diabetes.
Interpretation and limitations
Positive antibodies support type 1 diabetes. A negative panel raises monogenic probability only when combined with persistent C-peptide, age, family and phenotype evidence.
03
C-peptide with paired glucose
Why
Demonstrate endogenous insulin secretion at a time when glucose provides adequate stimulation.
Interpretation and limitations
Substantial secretion years after a presumed type 1 diagnosis supports reclassification. A low value during hypoglycaemia or acute illness cannot fairly exclude monogenic disease.
04
NHS genomic test
Why
Identify a pathogenic or likely pathogenic variant using the current National Genomic Test Directory eligibility and laboratory pathway.
Interpretation and limitations
Interpret classification, inheritance and phenotype together. A variant of uncertain significance is not diagnostic and should be reviewed with the reporting laboratory or clinical genetics service.
05
Renal ultrasound, eGFR and magnesium
Why
Look for the renal-developmental and electrolyte phenotype associated with HNF1B disease.
Interpretation and limitations
Structural renal abnormality or hypomagnesaemia strengthens the syndromic diagnosis and changes nephrology, medicine and family management; normal findings do not identify another MODY subtype.
06
Audiology and multisystem assessment
Why
Investigate suspected mitochondrial diabetes or another syndromic monogenic disorder beyond glycaemia.
Interpretation and limitations
Maternal transmission with sensorineural hearing loss supports mitochondrial disease and should prompt specialist cardiac, neurological and genetic advice according to the phenotype.
07
Fetal growth surveillance in GCK pregnancy
Why
Use growth trajectory as a clinical clue to fetal genotype when invasive diagnosis is not undertaken.
Interpretation and limitations
Accelerated growth may suggest an unaffected fetus exposed to maternal hyperglycaemia, while normal growth may be compatible with inheritance; decisions belong to a specialist antenatal diabetes-genetics team.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Type 1 diabetes

Diabetes autoantibodies, ketosis and very low C-peptide support autoimmune beta-cell destruction rather than a retained-secretion monogenic phenotype.

Young-onset type 2 diabetes

Insulin resistance, obesity and no dominant family pattern may favour type 2 disease, although phenotype alone cannot exclude a gene disorder.

Mitochondrial diabetes

Maternal transmission with hearing or other multisystem features suggests mitochondrial disease and distinct medicine considerations when supported by the history and examination.

Pancreatic diabetes

Pancreatitis, malabsorption or structural pancreatic disease indicates secondary loss of endocrine tissue rather than a primary beta-cell gene defect.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01SuspectBuild the monogenic caseFirst stepDiabetes age, family pattern or syndromic features do not fit routine type 1 or type 2 classification.

1Construct a three-generation pedigree and record exact diagnosis ages, therapies, birth histories, renal, hearing, neurological and pregnancy features.
2Review autoantibodies, paired C-peptide, HbA1c trajectory and current insulin safety, treating any active deficiency without waiting for genomic results.
3Discuss the case with a monogenic diabetes or genomic service and apply the current NHS test-directory eligibility and consent pathway to select the right test.

02TranslateAct on a confirmed resultA pathogenic or likely pathogenic variant is reported and matches the clinical phenotype.

1Verify the laboratory classification and inheritance with the specialist team, and explain what the result does and does not predict for this person.
2Change treatment only through the gene-specific plan: no routine therapy for most GCK disease, cautious sulfonylurea transfer for selected HNF1A or HNF4A disease, or insulin and organ-specific care where required.
3Document complication surveillance, medicine precautions, pregnancy implications and a fallback plan if the expected treatment response does not occur.

03FamilyOffer cascade and reproductive careA clinically actionable familial monogenic diagnosis has been confirmed.

1Refer through the appropriate genetics or monogenic service for consented targeted testing of eligible relatives rather than broad biochemical assumptions.
2Provide age-appropriate advice for relatives testing positive or negative, respecting their right not to know and the implications for insurance and family communication under UK practice.
3Arrange preconception and antenatal specialist review because maternal genotype, fetal genotype and treatment exposure can change growth and medicine decisions.

Key medicines and prescribing safety4 treatments · regimens, roles and cautions

Closes pancreatic potassium channels to stimulate insulin secretion and may provide effective treatment for selected hepatic nuclear factor diabetes.

Sulfonylurea for HNF1A or HNF4A diabetes

Begin only after specialist confirmation, using a lower-than-usual oral starting dose and slow titration against glucose because marked sensitivity is common; insulin transfer requires close supervision.

Hypoglycaemia can occur at small doses, particularly with missed meals, exercise or renal impairment. Do not extrapolate response to GCK, HNF1B or an unconfirmed genetic variant.

Replaces insulin when monogenic beta-cell dysfunction is advanced, during acute decompensation, or when a subtype does not respond safely to oral therapy.

Insulin

Use an individual basal-bolus, pump or neonatal specialist regimen according to current secretion, age, nutrition, pregnancy and glucose patterns; any reduction after genetic diagnosis must be supervised.

Abrupt withdrawal risks severe hyperglycaemia or ketosis. Teach hypoglycaemia, ketone and sick-day care, and maintain backup treatment during any gene-directed transition.

Can restore insulin secretion in selected pathogenic KCNJ11 or ABCC8 channel variants and may improve some neurological features.

High-dose sulfonylurea for KATP-channel neonatal diabetes

Use only the gene-specific transfer protocol in an experienced neonatal or monogenic diabetes centre, where doses may differ substantially from routine adult type 2 practice.

This is not empirical treatment for all neonatal diabetes. Specialist monitoring is essential during insulin withdrawal, gastrointestinal adverse effects and incomplete response.

May reduce hepatic glucose production when insulin resistance contributes, but it is not a universal monogenic treatment.

Metformin in mitochondrial or insulin-resistant phenotypes

Consider only after specialist subtype and organ-function review, using the licensed oral regimen and renal adjustment where its expected benefit outweighs risk.

Mitochondrial disease can heighten concern about lactate metabolism; follow expert advice and avoid during hypoxia, severe renal impairment, dehydration or acute metabolic illness.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Inappropriate treatment

Misclassification can expose a person to unnecessary insulin or withhold a genotype-responsive therapy, causing avoidable burden or poor control.

Pregnancy-related harm

Maternal and fetal genotype can affect fetal growth and the benefit or harm of glucose treatment, requiring specialist planning.

Unrecognised syndromic disease

Kidney, hearing, electrolyte or pancreatic manifestations may progress if the molecular diagnosis is treated as a glucose-only result.

Missed familial risk

Without governed cascade testing, relatives may remain misdiagnosed or unaware of their reproductive and clinical implications.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

For GCK-related hyperglycaemia outside pregnancy, avoid burdensome glucose surveillance while retaining a clear record so the stable phenotype is not repeatedly re-diagnosed or treated.
For HNF1A and HNF4A disease, monitor HbA1c, hypoglycaemia and progressive secretory failure and continue complication screening because vascular risk is clinically important.
For HNF1B disease, follow renal function, magnesium, blood pressure, liver biochemistry and pancreatic exocrine symptoms with nephrology or other specialists as indicated.
After any gene-directed medicine switch, review glucose frequently enough to identify both sulfonylurea hypoglycaemia and inadequate control, with a documented insulin restart threshold.
In pregnancy, coordinate maternal glucose and serial fetal growth through the antenatal diabetes and fetal-medicine service rather than using standard non-pregnant targets in isolation.
Update the pedigree when relatives are tested or new clinical features arise, and ensure variant reclassification from the laboratory reaches the clinical record.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

GCK treatment rarely moves glucose

The glucose set point is altered rather than driven by usual insulin resistance. Standard tablets or insulin often add burden without normalising the genetically determined fasting level.

Pregnancy reverses simple rules

Untreated maternal GCK hyperglycaemia may drive growth in an unaffected fetus, while aggressive treatment can restrict a fetus sharing the variant. Specialist genotype-informed surveillance is essential.

Urinary glucose is not a gene test

A low renal glucose threshold can occur in HNF1A disease, but glycosuria is neither sensitive nor specific enough to replace molecular confirmation.

HNF1B is more than diabetes

Renal malformation may precede dysglycaemia and the diabetes phenotype may not resemble other MODY. Magnesium and exocrine pancreas clues can unlock the diagnosis.

A VUS should create a question

A variant of uncertain significance prompts phenotype review, segregation work or future reinterpretation; it does not justify telling a family that disease is confirmed.

Genetic diagnosis scales care

One accurate result can change treatment for the proband and enable inexpensive targeted testing across relatives, but only when consent and variant interpretation are sound.

11Common pitfallsFrequent interpretation and management errors.

01
Calling every young adult with antibody-negative diabetes MODY without applying NHS phenotype and genomic testing criteria.
02
Stopping insulin before a reported variant is confirmed as pathogenic, phenotype-concordant and reviewed by the specialist team.
03
Treating stable GCK hyperglycaemia outside pregnancy simply to force HbA1c into a conventional diabetes target.
04
Using routine sulfonylurea doses in HNF1A disease and causing avoidable hypoglycaemia.
05
Missing HNF1B because no parent has diabetes despite renal abnormalities and a possible de novo deletion or variant.
06
Managing GCK pregnancy without considering fetal inheritance and serial growth.
07
Failing to offer consented cascade testing after a clear actionable familial diagnosis.